"Progress Towards a Vaccine for Lyme Disease."

According to the authors' abstract of an article published in Clinical Immunotherapeutics, "Although Lyme disease was first described no more than 20 years ago, knowledge has accumulated to the point that prototype vaccines are currently in advanced stages of clinical trials. A mouse model of Lyme disease facilitated efforts to describe protective immunity, which appears to depend mainly on the presence of antispirochaetal antibody. A recombinant major outer surface protein A (rOspA) fully protects mice and other hosts against infection and disease. A unique mode of action is apparent in that circulating antibody is ingested during the bloodmeal taken by the infectious tick, and serves...

Want to see the full article?

• Purchase this article for only $3.00